TR-1: NOTIFICATION OF MAJOR HOLDINGS

Ondine Biomedical Inc.
12 December 2023
 

Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS


1a. Identity of the issuer or the underlying issuer of existing shares:

Ondine Biomedical Inc

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of shares


An acquisition or disposal of financial instruments

X

An event changing the breakdown of shares outstanding


Other (please specify):


3. Details of person subject to the notification obligation

Name

Pentwater Capital Management LP

City and country of registered office (if applicable)

Naples, United States

4. Full name of shareholder(s) (if different from 3.)

Name


City and country of registered office (if applicable)


5. Date on which the threshold was crossed or reached:

08/12/2023

6. Date on which issuer notified (DD/MM/YYYY):

12/12/2023

7. Total positions of person(s) subject to the notification obligation


% of shares outstanding (total of 8. A)

% of shares outstanding through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of shares outstanding held in issuer

Resulting situation on the date on which threshold was crossed or reached


3.1026%

3.1026%

7,000,000.00

Position of previous notification (if

applicable)





 



 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedv

A: Shares

Class/type of
shares

ISIN code (if possible)

Number of shares outstanding

% of shares outstanding

Direct

 

Indirect

 

Direct

 

Indirect

 






SUBTOTAL 8. A



 

 

B 1: Financial Instruments as an entitlement to acquire

Type of financial instrument

Expiration
date

Exercise/
Conversion Period

Number shares that may be acquired if the instrument is

exercised/converted.

% of shares outstanding








SUBTOTAL 8. B 1



 

 

B 2: Financial Instruments with similar economic effect

Type of financial instrument

Expiration
date

Exercise/
Conversion Period

Physical or cash

settlement

Number of shares

% of shares outstanding

Swap

21/08/2030


Cash Settlement

7,000,000.00

3.1026%









 

SUBTOTAL 8.B.2

7,000,000.00

3.1026%

 

 

 

 

 

 

 



 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer

X

Full chain of controlled undertakings through which the shares and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity(please add additional rows as necessary)


Name

% of shares outstanding if it equals or is higher than the notifiable threshold

% of shares outstanding through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

























 

10. Additional information


 

Place of completion

Naples

Date of completion

12/12/2023

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings